Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)

Introduction: The selective Bcl-2 inhibitor venetoclax has shown promising therapeutic potential in multiple myeloma, particularly in cases associated with t(11;14) IGH::CCND1 translocation. However, the efficacy of venetoclax in myeloma patients with the t(6;14) IGH::CCND3 translocation remains les...

Full description

Bibliographic Details
Main Authors: Andrea Ceglédi, Zoltán Csukly, Mónika Fekete, András Kozma, Zsuzsanna Szemlaky, Hajnalka Andrikovics, Gábor Mikala
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Pathology and Oncology Research
Subjects:
multiple myeloma
venetoclax
translocation t(6;14)
IGH::CCND3
personalized therapy
Online Access:https://www.por-journal.com/articles/10.3389/pore.2023.1611375/full

Internet

https://www.por-journal.com/articles/10.3389/pore.2023.1611375/full

Similar Items